In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Verve Therapeutics Inc (NASDAQ: VERV) closed at $11.17 in the last session, up 0.54% from day before closing price of $11.11. In other words, the price has increased by $0.54% from its previous closing price. On the day, 2.99 million shares were traded. VERV stock price reached its highest trading level at $11.19 during the session, while it also had its lowest trading level at $11.09.
Ratios:
We take a closer look at VERV’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.84 and its Current Ratio is at 9.84. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.12.
On April 08, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.
On April 13, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $29.Canaccord Genuity initiated its Buy rating on April 13, 2023, with a $29 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 02 ’25 when Kathiresan Sekar sold 9,822 shares for $4.15 per share. The transaction valued at 40,761 led to the insider holds 346,686 shares of the business.
Nickerson Joan sold 2,777 shares of VERV for $11,525 on Apr 02 ’25. The Chief Administrative Officer now owns 17,420 shares after completing the transaction at $4.15 per share. On Apr 02 ’25, another insider, Ashe Andrew D., who serves as the insider of the company, sold 2,681 shares for $4.15 each. As a result, the insider received 11,126 and left with 348,828 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VERV now has a Market Capitalization of 997617280 and an Enterprise Value of 567288960. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.70 while its Price-to-Book (P/B) ratio in mrq is 2.09. Its current Enterprise Value per Revenue stands at 9.516 whereas that against EBITDA is -2.814.
Stock Price History:
The Beta on a monthly basis for VERV is 1.83, which has changed by 1.2250996 over the last 52 weeks, in comparison to a change of 0.11213791 over the same period for the S&P500. Over the past 52 weeks, VERV has reached a high of $11.40, while it has fallen to a 52-week low of $2.86. The 50-Day Moving Average of the stock is 99.39%, while the 200-Day Moving Average is calculated to be 91.42%.
Shares Statistics:
According to the various share statistics, VERV traded on average about 5.19M shares per day over the past 3-months and 12337160 shares per day over the past 10 days. A total of 88.80M shares are outstanding, with a floating share count of 65.76M. Insiders hold about 26.23% of the company’s shares, while institutions hold 74.01% stake in the company. Shares short for VERV as of 1748563200 were 19844745 with a Short Ratio of 3.83, compared to 1745971200 on 18514749. Therefore, it implies a Short% of Shares Outstanding of 19844745 and a Short% of Float of 26.369999999999997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Verve Therapeutics Inc (VERV) is currently drawing attention from 10.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.7, with high estimates of -$0.53 and low estimates of -$0.88.
Analysts are recommending an EPS of between -$1.83 and -$2.98 for the fiscal current year, implying an average EPS of -$2.43. EPS for the following year is -$2.75, with 9.0 analysts recommending between -$1.96 and -$3.81.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for VERV’s current fiscal year. The highest revenue estimate was $72.22M, while the lowest revenue estimate was $12.3M, resulting in an average revenue estimate of $42.15M. In the same quarter a year ago, actual revenue was $32.33M
